In this review:
- Gilteritinib vs. midostaurin in newly diagnosed FLT3-mutated AML
- Adding low-dose cytarabine to venetoclax-azacitidine in older newly diagnosed AML
- Azacitidine + reduced-duration venetoclax in AML
- Debate: does blast count count in MDS/AML diagnosis?
- DDX41 germline predisposition: genetic classification, clinical aspects and management
- IDH1 and IDH2 as molecular markers for MRD monitoring in AML
- Early vs. delayed ropeginterferon alfa-2B in high-risk essential thrombocythaemia
- Algorithm for risk stratifying relapsed/refractory AML undergoing allogeneic HSCT
- Treatment options in VEXAS
- Debate: role of autologous transplantation in mantle cell lymphoma
- High-risk cytogenetics in myeloma: definition and treatment options
Please login below to download this issue (PDF)